Site Editors

Alexander Drilon, MD

Gregory J. Riely, MD, PhD


ASCO 2022: Health-Related Quality of Life With Larotrectinib for TRK-Fusion Cancer

By: Sarah Campen, PharmD
Posted: Tuesday, June 14, 2022

Patients with TRK-fusion cancer who are treated with the central nervous system–active TRK inhibitor larotrectinib appear to have significant improvements in health-related quality of life, according to a study presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract 6563). Shivaani Kummar, MD, FACP, of Stanford Cancer Center and Stanford University, Palo Alto, California, and colleagues described these improvements in quality of life as “rapid, clinically meaningful, and sustained.”

This study included 113 patients who were participating in two ongoing trials of larotrectinib for the treatment of TRK-fusion cancer. Patients completed health-related quality-of-life questionnaires, including the European Organisation for the Research and Treatment of Cancer Quality-of-Life Questionnaire (EORTC QLQ-C30) and the EuroQol 5 Dimension 5 Level (EQ-5D-5L) at baseline and at least once after treatment was initiated.

According to the investigators, most patients had clinically meaningful health-related quality-of-life improvements during treatment. After 2 months of treatment, 75% of adults reported health-related quality-of-life improvements from baseline. The median durations of sustained improvement (as assessed by the EORTC QLQ-C30 global health score and the EQ-5D-5L visual analog scale) were 12.5 months and 12.9 months, respectively. Additionally, most adults had maintained or improved scores from baseline at or above the normal population level category, as determined by the EORTC QLQ-C30 global health score.

Disclosure: For full disclosures of the study authors, visit

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.